Johnson & Johnson (JNJ) Cash & Current Investments (2009 - 2026)

Johnson & Johnson's (JNJ) quarterly Cash & Current Investments came in at $22.1 billion in Q1 2026, down 43.14% year-on-year from $38.8 billion in Q1 2025, and up 9.7% quarter-over-quarter from $20.1 billion in Q4 2025.

Johnson & Johnson (JNJ) Cash & Current Investments (2009 - 2026) Analysis & Trends

Johnson & Johnson has disclosed Cash & Current Investments across 18 years of filings, most recently posting $22.1 billion for Q1 2026.

  • Cash & Current Investments for Q1 2026 came in at $22.1 billion, down 43.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $22.1 billion (down 43.14% YoY), and the FY2025 annual result was $20.1 billion, down 18.02% from the prior year.
  • Cash & Current Investments came in at $22.1 billion for Q1 2026 at Johnson & Johnson, up from $20.1 billion in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $38.8 billion in Q1 2025 to a low of $18.6 billion in Q3 2025.
  • The 5-year median for Cash & Current Investments is $24.6 billion (2023), against an average of $25.9 billion.
  • Across the five-year window, Cash & Current Investments jumped 47.92% in 2025 and tumbled 43.14% in 2026, its largest moves.
  • Johnson & Johnson's Cash & Current Investments stood at $34.1 billion in 2022, then sank by 32.72% to $22.9 billion in 2023, then gained by 6.96% to $24.5 billion in 2024, then fell by 18.02% to $20.1 billion in 2025, then advanced by 9.7% to $22.1 billion in 2026.
  • The last three Cash & Current Investments figures came in at $22.1 billion (Q1 2026), $20.1 billion (Q4 2025), and $18.6 billion (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Current Investments (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn 4.38 Bn
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn 5.28 Bn
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn 22.05 Bn
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn 9.39 Bn
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn 5.70 Bn
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn 12.04 Bn
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn 7.64 Bn
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn 13.08 Bn
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn 10.49 Bn
10 Novartis Ag 108.28 Bn 107.60 Bn - 100.00 Mn

Historic Data

Download Data
DateValue
Mar 29, 2026 22.05 Bn
Dec 28, 2025 20.10 Bn
Sep 28, 2025 18.56 Bn
Jun 29, 2025 18.88 Bn
Mar 30, 2025 38.78 Bn
Dec 29, 2024 24.52 Bn
Sep 29, 2024 20.30 Bn
Jun 30, 2024 25.48 Bn
Mar 31, 2024 26.22 Bn
Dec 31, 2023 22.93 Bn
Oct 1, 2023 23.51 Bn
Jul 2, 2023 28.51 Bn
Apr 2, 2023 24.61 Bn
Jan 1, 2023 22.28 Bn
Oct 2, 2022 34.08 Bn
Jul 3, 2022 32.57 Bn
Apr 3, 2022 30.39 Bn
Jan 2, 2022 31.61 Bn
Oct 3, 2021 31.00 Bn
Jul 4, 2021 25.31 Bn